Consequences of Disrupting the Dystrophin-Sarcoglycan Complex in Cardiac and Skeletal Myopathy

Trends in Cardiovascular Medicine

Volumn 17, Issue 2, 2007, Pages 55-59

  Heydemann, Ahlke ^a   McNally, Elizabeth M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA DYSTROGLYCAN; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEURONAL NITRIC OXIDE SYNTHASE; POLOXAMER; SARCOGLYCAN;

CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; COXSACKIE VIRUS B; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; HEART MUSCLE; HEART PROTECTION; HUMAN; MIYOSHI MYOPATHY; MUSCLE ATROPHY; MUSCULAR DYSTROPHY; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMERE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STRESS; VASOSPASM; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CARDIOMYOPATHIES; DYSTROPHIN; HUMANS; MUSCLE, SKELETAL; MUSCLE, SMOOTH, VASCULAR; MUSCULAR DISEASES; MUTATION; SARCOGLYCANS; SIGNAL TRANSDUCTION;

EID: 33846781220     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2006.12.002     Document Type: Review

References (41)

1. Armstrong S.C., Latham C.A., Shivell C.L., and Ganote C.E. Ischemic loss of sarcolemmal dystrophin and spectrin: correlation with myocardial injury. J Mol Cell Cardiol 33 (2001) 1165-1179
2. Badorff C., and Knowlton K.U. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol (Berl) 193 (2004) 121-126
3. Barton E.R. Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle. Am J Physiol Cell Physiol 290 (2006) C411-C419
4. Basset O., Boittin F.X., Cognard C., et al. Bcl-2 overexpression prevents calcium overload and subsequent apoptosis in dystrophic myotubes. Biochem J 395 (2006) 267-276
5. Betto R., Senter L., Ceoldo S., et al. Ecto-ATPase activity of alpha-sarcoglycan (adhalin). J Biol Chem 274 (1999) 7907-7912
6. Danko I., Chapman V., and Wolff J.A. The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr Res 32 (1992) 128-131
7. Dell'Agnola C., Wang Z., Storb R., et al. Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. Blood 104 (2004) 4311-4318
8. Doherty K.R., Cave A., Davis D.B., et al. Normal myoblast fusion requires myoferlin. Development 132 (2005) 5565-5575
9. Duboc D., Meune C., Lerebours G., et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45 (2005) 855-857
10. Gee S.H., Madhavan R., Levinson S.R., et al. Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins. J Neurosci 18 (1998) 128-137
11. Griffin M.A., Feng H., Tewari M., et al. Gamma-sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect adhesion. J Cell Sci 118 (2005) 1405-1416
12. Hack A.A., Cordier L., Shoturma D.I., et al. Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc Natl Acad Sci U S A 96 (1999) 10723-10728
13. Hack A.A., Ly C.T., Jiang F., et al. Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J Cell Biol 142 (1998) 1279-1287
14. Hainsey T.A., Senapati S., Kuhn D.E., and Rafael J.A. Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscul Disord 13 (2003) 294-302
15. Heydemann A., Huber J.M., Kakkar R., et al. Functional nitric oxide synthase mislocalization in cardiomyopathy. J Mol Cell Cardiol 36 (2004) 213-223
16. Heydemann A., Demonbreun A., Hadhazy M., et al. Nuclear sequestration of δ-sarcoglycan disrupts the nuclear localization of lamin A/C and emerin in cardiomyocytes. Hum Mol Genet (2006) (in press)
17. Hoffman E.P., Morgan J.E., Watkins S.C., and Partridge T.A. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neurol Sci 99 (1990) 9-25
18. Holt K.H., and Campbell K.P. Assembly of the sarcoglycan complex. Insights for muscular dystrophy. J Biol Chem 273 (1998) 34667-34670
19. Ichihara S., Yamada Y., Ichihara G., et al. Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. Biochem Biophys Res Commun 350 (2006) 105-113
20. Jefferies J.L., Eidem B.W., Belmont J.W., et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 112 (2005) 2799-2804
21. Kyoi S., Otani H., Matsuhisa S., et al. Role of oxidative/nitrosative stress in the tolerance to ischemia/reperfusion injury in cardiomyopathic hamster heart. Antioxid Redox Signal 8 (2006) 1351-1361
22. Lapidos K.A., Chen Y.E., Earley J.U., et al. Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. J Clin Invest 114 (2004) 1577-1585
23. Lee G.H., Badorff C., and Knowlton K.U. Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. Circ Res 87 (2000) 489-495
24. Matsumura K., Arai K., Zhong D., et al. Disruption of dystroglycan axis by beta-dystroglycan processing in cardiomyopathic hamster muscle. Neuromuscul Disord 13 (2003) 796-803
25. Matsumura K., Zhong D., Saito F., et al. Proteolysis of beta-dystroglycan in muscular diseases. Neuromuscul Disord 15 (2005) 336-341
26. Oak S.A., Russo K., Petrucci T.C., and Jarrett H.W. Mouse alpha1-syntrophin binding to Grb2: further evidence of a role for syntrophin in cell signaling. Biochemistry 40 (2001) 11270-11278
27. Rodriguez M., Cai W.J., Kostin S., et al. Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol 38 (2005) 723-733
28. Rosenzweig A. Cardiac cell therapy-mixed results from mixed cells. N Engl J Med 355 (2006) 1274-1277
29. Rybakova I.N., Patel J.R., and Ervasti J.M. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 150 (2000) 1209-1214
30. Sakamoto A., Ono K., Abe M., et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci U S A 94 (1997) 13873-13878
31. Sandona D., Gastaldello S., Martinello T., and Betto R. Characterization of the ATP-hydrolysing activity of alpha-sarcoglycan. Biochem J 381 (2004) 105-112
32. Shelton G.D., and Engvall E. Canine and feline models of human inherited muscle diseases. Neuromuscul Disord 15 (2005) 127-138
33. Tews D.S. Apoptosis and muscle fibre loss in neuromuscular disorders. Neuromuscul Disord 12 (2002) 613-622
34. Tews D.S. Tumour necrosis factor-mediated cell death pathways do not contribute to muscle fibre death in dystrophinopathies. Acta Neuropathol (Berl) 109 (2005) 217-225
35. Thompson T.G., Chan Y.M., Hack A.A., et al. Filamin 2 (FLN2): a muscle-specific sarcoglycan interacting protein. J Cell Biol 148 (2000) 115-126
36. Vatta M., Stetson S.J., Perez-Verdia A., et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 359 (2002) 936-941
37. Wheeler M.T., Allikian M.J., Heydemann A., et al. Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J Clin Invest 113 (2004) 668-675
38. Yamada H., Saito F., Fukuta-Ohi H., et al. Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 10 (2001) 1563-1569
39. Yang B., Jung D., Motto D., et al. SH3 domain-mediated interaction of dystroglycan and Grb2. J Biol Chem 270 (1995) 11711-11714
40. Yasuda S., Townsend D., Michele D.E., et al. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 436 (2005) 1025-1029
41. Yoshida T., Pan Y., Hanada H., et al. Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes. J Biol Chem 273 (1998) 1583-1590